SEC Form 4 · accession 0001628280-26-056108
Vir Biotechnology, Inc. · VIR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J More
Director
Period of report
Aug 11, 2026
Accepted (ET)
Aug 12, 2026 · 2:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001706431
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 11, 2026 | J | 8,000 | $0.00 | D | 40,656 | D | |
| Common StockF2 | Aug 11, 2026 | J | 8,000 | $0.00 | A | 517,917 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards.
- F2The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.